Fucis tablets 200 mg. №4

Description

Fucis 200 mg Composition

active substance: fluconazole (fluconazole) 1 tablet contains fluconazole 50 mg or 100 mg or 150 mg or 200 mg
excipients: lactose, microcrystalline cellulose, povidone KZ0, talc, magnesium stearate, sodium starch (type A), croscarmellose sodium.

Fucis 200 mg Dosage form

Pills.

Basic physical and chemical properties:

white, round tablets with beveled edges, with a break line on one side.

Pharmacological group

ATX code. Antifungal agents for systemic use. Triazole derivatives. ATX code J02A C01.

Pharmacological properties

Pharmacological.

Fluconazole, an antifungal drug of the triazole class, is a potent and selective inhibitor of fungal enzymes required for the synthesis of ergosterol. The primary mechanism of its action is the suppression of fungal 14 alpha-lanosterol demethylation, mediated by cytochrome P450, which is an integral step in the biosynthesis of fungal ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol by the membrane of the fungal cell and may be responsible for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.

The use of fluconazole at a dose of 50 mg per day for 28 days does not affect the level of testosterone in the blood plasma in men or the level of endogenous steroids in women of reproductive age. Fluconazole at a dose of 200-400 mg per day does not show a clinically significant effect on the level of endogenous steroids or the response to ACTH stimulation in healthy male volunteers.

The study of interaction with antipyrine demonstrated that the use of 50 mg of fluconazole once or repeatedly does not affect the metabolism of antipyrine.

Indications

Treatment of such diseases in adults as:

cryptococcal meningitis
coccidioidomycosis
invasive candidiasis
mucosal candidiasis, including oropharyngeal candidiasis and esophageal candidiasis candiduria, chronic skin and mucous membrane candidiasis
chronic atrophic candidiasis (candidiasis caused by the use of dentures) with ineffective local dental hygiene products
vaginal candidiasis, acute or recurrent when local therapy is inappropriate
candidal balanitis when topical therapy is inappropriate
dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal tinea versicolor and candidal skin infections when systemic therapy is inappropriate
dermatophytic onychomycosis, when the use of other drugs is inappropriate.
Prevention of such diseases in adults as:

relapse of cryptococcal meningitis in patients at high risk of developing it
recurrent oropharyngeal or esophageal candidiasis in HIV-infected patients at high risk of developing it
a decrease in the frequency of relapses of vaginal candidiasis (4 or more cases per year)
prevention of candidal infections in patients with prolonged neutropenia (for example, patients with malignant blood diseases receiving chemotherapy or patients with hematopoietic stem cell transplantation).